Trial
NCT04569760
Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
McMaster University
Collaborators
MediPharm Labs Corp
Condition
Generalized Anxiety Disorder
Intervention
50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose)
Why stopped
Project cancelled prior to commencing recruitment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-03-24